Go to
JCI Insight
Paul Marks
Paul Marks is recognized as a leader in the cancer field and as a world-class scientist, clinician, and administrator. He served as president and CEO of Memorial Sloan-Kettering Cancer Center (MSKCC) between 1980 and 1999 after serving as the dean (1970–1973) and vice president for Medical Sciences (1973–1980) of the Columbia University College of Physicians and Surgeons (P&S). Marks led the discovery, testing, and recent approval of SAHA (suberoylanilide hydroxamic acid), the treatment for cutaneous T-cell lymphoma. SAHA and other histone deacetylase (HDAC) inhibitors are now undergoing trials for a broad array of cancers.
Published October 1, 2012, by The JCI
Related articles
Follow JCI:
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)